Skip to main content
padlock icon - secure page this page is secure

In vitro and in vivo Anticancer Activities of Folate-Decorated Vinorelbine Bitartrate-Loaded Recombinant Human Serum Albumin Nanoparticles

Buy Article:

$68.00 + tax (Refund Policy)

Background: Vinorelbine bitartrate (VB), an important anticancer drug, is used to treat varieties of cancers in clinical, but its side effects when directly administered as an aqueous solution limit its application.

Objective: To test anti-tumor activities of folate-decorated vinorelbine bitartrate-loaded recombinant human serum albumin nanoparticles (FA-rHSA-VBNPs).

Method: A desolvation procedure was used to prepare vinorelbine bitartrate nanoparticles, then crosslinked with recombinant human serum albumin, and finally decorated with folic acid. The nanoparticles #39; surface morphology and particle size distribution were investigated in vitro. The in vitro antiproliferative activities were tested by the MTT assay, and the in vivo anti-tumor activities were investigated using S180 bearing mice.

Result: We obtained spherical nanoparticles of 180 nm, and its size distribution was narrow. FArHSA- VBNPs and VB injection inhibited HO-8910, SK-OV-3, MCF-7, MX-1 and A-549 well, but showed little effect on Bel-7402, HepG-2 and PC-3. At 2 mg/kg, VB-FA-rHSANPs inhibited S180 by 83.20%, whereas VB injection inhibited 63.50%.

Conclusion: In general, FA-rHSA-VBNPs exhibited much better cytotoxicity to all cancer cell lines than VB injection, and showed a dose-dependent effect in the survival towards the eight tumor cell lines. The cytotoxicity of FA-rHSA-VBNPs and VB injection on HO-8910 was significantly stronger than on the other seven human cancer cell lines. FA-rHSA-VBNPs showed much better anti-tumor activity against S180 than VB injection. FA-rHSA-VBNPs showed much better activities than VB injection both in vitro and in vivo anticancer tests.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Vinorelbine bitartrate; anticancer activities; folic acid; human serum albumin; nanoparticles; target delivery

Document Type: Research Article

Publication date: August 1, 2018

More about this publication?
  • Current Nanoscience publishes authoritative reviews and original research reports, written by experts in the field on all the most recent advances in nanoscience and nanotechnology. All aspects of the field are represented including nano- structures, synthesis, properties, assembly and devices. Applications of nanoscience in biotechnology, medicine, pharmaceuticals, physics, material science and electronics are also covered. The journal is essential to all involved in nanoscience and its applied areas.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more